AU2013290168A1 - Tri-salt form of metformin - Google Patents

Tri-salt form of metformin Download PDF

Info

Publication number
AU2013290168A1
AU2013290168A1 AU2013290168A AU2013290168A AU2013290168A1 AU 2013290168 A1 AU2013290168 A1 AU 2013290168A1 AU 2013290168 A AU2013290168 A AU 2013290168A AU 2013290168 A AU2013290168 A AU 2013290168A AU 2013290168 A1 AU2013290168 A1 AU 2013290168A1
Authority
AU
Australia
Prior art keywords
compound
metformin
subject
formula
eicosapentaenoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013290168A
Other languages
English (en)
Inventor
Banavara L. Mylari
Frank C. Sciavolino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thetis Pharmaceuticals LLC
Original Assignee
Thetis Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,970 external-priority patent/US8765811B2/en
Application filed by Thetis Pharmaceuticals LLC filed Critical Thetis Pharmaceuticals LLC
Publication of AU2013290168A1 publication Critical patent/AU2013290168A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2013290168A 2012-07-10 2013-07-10 Tri-salt form of metformin Abandoned AU2013290168A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261669763P 2012-07-10 2012-07-10
US61/669,763 2012-07-10
US201261670368P 2012-07-11 2012-07-11
US201261670376P 2012-07-11 2012-07-11
US61/670,368 2012-07-11
US61/670,376 2012-07-11
US13/841,970 US8765811B2 (en) 2012-07-10 2013-03-15 Tri-salt form of metformin
US13/841,970 2013-03-15
PCT/US2013/049984 WO2014011814A1 (en) 2012-07-10 2013-07-10 Tri-salt form of metformin

Publications (1)

Publication Number Publication Date
AU2013290168A1 true AU2013290168A1 (en) 2015-02-05

Family

ID=49916541

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013290168A Abandoned AU2013290168A1 (en) 2012-07-10 2013-07-10 Tri-salt form of metformin

Country Status (12)

Country Link
EP (1) EP2872483A4 (pt)
JP (1) JP2015523382A (pt)
KR (1) KR20150036235A (pt)
CN (1) CN104684889A (pt)
AU (1) AU2013290168A1 (pt)
BR (1) BR112015000368A2 (pt)
CA (1) CA2878819A1 (pt)
IL (1) IL236613A0 (pt)
IN (1) IN2015KN00076A (pt)
MX (1) MX2015000408A (pt)
WO (1) WO2014011814A1 (pt)
ZA (1) ZA201500274B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853259B2 (en) * 2013-02-07 2014-10-07 Banavara L. Mylari Metformin derivatives for treating diabetes and diabetes complications
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
DK3157936T3 (en) * 2014-06-18 2019-02-04 Thetis Pharmaceuticals Llc MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES
US20170119841A1 (en) * 2015-11-04 2017-05-04 Thetis Pharmaceuticals Llc Amino acid salts of unsaturated fatty acids
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
US10471963B2 (en) 2017-04-07 2019-11-12 TuSimple System and method for transitioning between an autonomous and manual driving mode based on detection of a drivers capacity to control a vehicle
US10737695B2 (en) 2017-07-01 2020-08-11 Tusimple, Inc. System and method for adaptive cruise control for low speed following
CN113105367B (zh) * 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用
CN116999398A (zh) * 2022-06-30 2023-11-07 山东海赜生物科技有限公司 一种口服组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
AU2001213150A1 (en) * 2000-08-03 2002-02-18 Olga Evgenievna Kolesova Composition of metformin with succinic acid or salts thereof and method for treating diabetes
EP1605781A1 (en) * 2003-03-18 2005-12-21 Novartis AG Compositions comprising fatty acids and amino acids
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
JP5292404B2 (ja) * 2007-09-21 2013-09-18 ハンオル バイオファーマ カンパニー，リミテッド Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物
WO2009080022A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum tablet
WO2009151116A1 (ja) * 2008-06-13 2009-12-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
AU2010241567B2 (en) * 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
CN104220875A (zh) * 2010-10-19 2014-12-17 埃尔舍利克斯治疗公司 基于化学感应受体配体的治疗
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US8853259B2 (en) * 2013-02-07 2014-10-07 Banavara L. Mylari Metformin derivatives for treating diabetes and diabetes complications

Also Published As

Publication number Publication date
CA2878819A1 (en) 2014-01-16
IN2015KN00076A (pt) 2015-07-31
WO2014011814A1 (en) 2014-01-16
EP2872483A1 (en) 2015-05-20
EP2872483A4 (en) 2016-03-16
CN104684889A (zh) 2015-06-03
IL236613A0 (en) 2015-02-26
BR112015000368A2 (pt) 2017-06-27
MX2015000408A (es) 2015-07-14
KR20150036235A (ko) 2015-04-07
JP2015523382A (ja) 2015-08-13
ZA201500274B (en) 2017-10-25

Similar Documents

Publication Publication Date Title
AU2013290168A1 (en) Tri-salt form of metformin
US8765811B2 (en) Tri-salt form of metformin
ES2718047T3 (es) Triterpenoides sintéticos y métodos de uso en el tratamiento de la enfermedad
KR101704683B1 (ko) 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
AU2012205547B2 (en) Lipid-lowering antidiabetic agent
SK14922002A3 (sk) Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru
WO2014008374A2 (en) Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
US9382187B2 (en) Tri-salt form of metformin
TW516959B (en) Composition containing ascorbic acid
US8252840B2 (en) Methods of derivatives of probucol for the treatment of type II diabetes
WO2014008379A2 (en) Diamine and meglumine salt forms of fatty acids
WO2012154392A1 (en) Metformin salts of salicylic acid and its congeners
US20110060156A1 (en) Pyruvate Derivatives with Neuroprotective Effect, Process for Preparing the Same and Pharmaceutical Composition Comprising the Same
US20080280985A1 (en) Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
WO2009085223A1 (en) Combination of metformin r-(+)-lipoate and antihyperglycemic agents for the treatment of diabetic hyperglycemia and diabetic complications
JP2021024826A (ja) 糖化産物生成抑制剤及び医薬組成物

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period